MDx market analysis and updates

Large infrastructure investments in clinical laboratories since the covid-19 pandemic, along with rapid development of new diagnostic technologies are opening up new opportunities to enable personalised treatment, disease monitoring and improve patient outcomes for the world’s population through molecular diagnostics (MDx).

Clearstate offers market data, forecasts, and trend predictions to give you the insight to adjust your business strategy to meet the growing opportunities in molecular diagnostics. Our MDx hub is regularly updated to share our findings on this fast-growing diagnostic market segment. 

What is molecular diagnostics (MDx)?

Molecular diagnostics (MDx) identify and quantify the presence of biomarkers or genetic material which are linked to different types of diseases. MDx tests are carried out at laboratories or other decentralised testing locations such as specialised departments within hospitals using molecular techniques such as PCR, real-time PCR (rtPCR), qPCR or sequencing.

Explore the latest MDx market insights

From market news to analysis, our articles provide concise and up-to-date information about the developments driving MDx market growth. Explore the latest in MDx technology and test applications from companion diagnostics to infectious disease screening as new solutions are developed and adopted in the market. Understand the implications of the emergence of MDx alternatives to traditional culture-based testing and immunoassays, and examine the issues that arise from growing competition in this segment of the market. 

Understand the molecular diagnostics market

Discover more IVD insights or learn how our IVD Gateway solution can help prepare your business for the future impact of the world’s expanding molecular diagnostic testing capacities. 

Clearstate newsletter

Sign up to our newsletter for insights into key market data, trends and developments across IVD and Surgical segments from our specialists and analysts.